Counseling about risks of congenital anomalies from prescription opioids
Identifieur interne : 001E49 ( Main/Exploration ); précédent : 001E48; suivant : 001E50Counseling about risks of congenital anomalies from prescription opioids
Auteurs : Matthew C. Brennan [États-Unis] ; William F. Rayburn [États-Unis]Source :
- Birth Defects Research Part A: Clinical and Molecular Teratology [ 1542-0752 ] ; 2012-08.
English descriptors
- Teeft :
- Additional risks, American institute, Analgesic, Anomaly, Birth defects, Birth defects research, Broussard, Buprenorphine, Buprenorphine exposure, Cardiac, Cardiac defects, Case reports, Codeine, Combination medications, Congenital, Congenital anomalies, Congenital heart disease, Congenital malformations, Counseling patients, Counseling women, Defect, Early pregnancy, Fetal, Fetal echocardiographic examination, Fetal effects, Gynecol, Large study, Malformation, Medication, Mental health services administration, Methadone, Mexico school, National birth defects prevention study, National survey, Neonatal abstinence syndrome, Neonatal outcome, Neural tube defects, Nuchal translucency, Obstet, Opioid, Opioid analgesics, Opioid dependency, Opioid exposure, Opioid growth factor, Opioid growth factor receptors, Opioid medications, Opioid treatment, Opioids, Oral clefts, Other drugs, Other factors, Patient comprehension, Potential risks, Pregnancy, Pregnant women, Prescription, Prescription opioids, Retrospective studies, Rothman, Serum testing, Spontaneous abortion, Subst abuse, Substance abuse, Surgical procedures, Teratogen warning label, Teratogenic, Trade names, Trimester, Ultrasound, Wiley periodicals.
Abstract
The use of prescription opioids is becoming an increasing problem among women of reproductive age. More than half of pregnancies are unintended; therefore, many first‐trimester exposures to opioids occur before pregnancy confirmation. Studies are limited about the fetal risks to opioid exposure in early pregnancy. One large study demonstrated an increased risk of certain heart defects and spina bifida with first‐trimester exposure to opioids. It is important to counsel women whose fetuses were exposed to opioids in early pregnancy about the potential risks, encourage them to cease using opioids or seek alternative treatments when appropriate, and use the lowest effective dose when opioid treatment is to be continued. It is also valuable to screen for anatomic abnormalities such as neural tube and cardiac defects with available maternal serum testing and ultrasound imaging in the early second trimester. Birth Defects Research (Part A) 94:620–625, 2012. © 2012 Wiley Periodicals, Inc.
Url:
DOI: 10.1002/bdra.23064
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002827
- to stream Istex, to step Curation: 002794
- to stream Istex, to step Checkpoint: 000438
- to stream Main, to step Merge: 001E68
- to stream Main, to step Curation: 001E49
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Counseling about risks of congenital anomalies from prescription opioids</title><author><name sortKey="Brennan, Matthew C" sort="Brennan, Matthew C" uniqKey="Brennan M" first="Matthew C." last="Brennan">Matthew C. Brennan</name></author><author><name sortKey="Rayburn, William F" sort="Rayburn, William F" uniqKey="Rayburn W" first="William F." last="Rayburn">William F. Rayburn</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A9FC8F07129E3C3062B52166DECFB33015BBF83D</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1002/bdra.23064</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-64F30DJC-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002827</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002827</idno><idno type="wicri:Area/Istex/Curation">002794</idno><idno type="wicri:Area/Istex/Checkpoint">000438</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000438</idno><idno type="wicri:doubleKey">1542-0752:2012:Brennan M:counseling:about:risks</idno><idno type="wicri:Area/Main/Merge">001E68</idno><idno type="wicri:Area/Main/Curation">001E49</idno><idno type="wicri:Area/Main/Exploration">001E49</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Counseling about risks of congenital anomalies from prescription opioids</title><author><name sortKey="Brennan, Matthew C" sort="Brennan, Matthew C" uniqKey="Brennan M" first="Matthew C." last="Brennan">Matthew C. Brennan</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Nouveau-Mexique</region></placeName><wicri:cityArea>Milagro Clinic for Pregnant Women with Substance Use Disorders, Division of Maternal‐Fetal Medicine, Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque</wicri:cityArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Nouveau-Mexique</region></placeName><wicri:cityArea>Correspondence address: Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, MSC 10 5580, 1 University of New Mexico, Albuquerque</wicri:cityArea></affiliation></author><author><name sortKey="Rayburn, William F" sort="Rayburn, William F" uniqKey="Rayburn W" first="William F." last="Rayburn">William F. Rayburn</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Nouveau-Mexique</region></placeName><wicri:cityArea>Milagro Clinic for Pregnant Women with Substance Use Disorders, Division of Maternal‐Fetal Medicine, Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Birth Defects Research Part A: Clinical and Molecular Teratology</title><title level="j" type="sub">OTIS 25th Anniversary Issue</title><title level="j" type="alt">BIRTH DEFECTS RESEARCH PART A: CLINICAL AND MOLECULAR TERATOLOGY</title><idno type="ISSN">1542-0752</idno><idno type="eISSN">1542-0760</idno><imprint><biblScope unit="vol">94</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="620">620</biblScope><biblScope unit="page" to="625">625</biblScope><biblScope unit="page-count">6</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-08">2012-08</date></imprint><idno type="ISSN">1542-0752</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1542-0752</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Additional risks</term><term>American institute</term><term>Analgesic</term><term>Anomaly</term><term>Birth defects</term><term>Birth defects research</term><term>Broussard</term><term>Buprenorphine</term><term>Buprenorphine exposure</term><term>Cardiac</term><term>Cardiac defects</term><term>Case reports</term><term>Codeine</term><term>Combination medications</term><term>Congenital</term><term>Congenital anomalies</term><term>Congenital heart disease</term><term>Congenital malformations</term><term>Counseling patients</term><term>Counseling women</term><term>Defect</term><term>Early pregnancy</term><term>Fetal</term><term>Fetal echocardiographic examination</term><term>Fetal effects</term><term>Gynecol</term><term>Large study</term><term>Malformation</term><term>Medication</term><term>Mental health services administration</term><term>Methadone</term><term>Mexico school</term><term>National birth defects prevention study</term><term>National survey</term><term>Neonatal abstinence syndrome</term><term>Neonatal outcome</term><term>Neural tube defects</term><term>Nuchal translucency</term><term>Obstet</term><term>Opioid</term><term>Opioid analgesics</term><term>Opioid dependency</term><term>Opioid exposure</term><term>Opioid growth factor</term><term>Opioid growth factor receptors</term><term>Opioid medications</term><term>Opioid treatment</term><term>Opioids</term><term>Oral clefts</term><term>Other drugs</term><term>Other factors</term><term>Patient comprehension</term><term>Potential risks</term><term>Pregnancy</term><term>Pregnant women</term><term>Prescription</term><term>Prescription opioids</term><term>Retrospective studies</term><term>Rothman</term><term>Serum testing</term><term>Spontaneous abortion</term><term>Subst abuse</term><term>Substance abuse</term><term>Surgical procedures</term><term>Teratogen warning label</term><term>Teratogenic</term><term>Trade names</term><term>Trimester</term><term>Ultrasound</term><term>Wiley periodicals</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The use of prescription opioids is becoming an increasing problem among women of reproductive age. More than half of pregnancies are unintended; therefore, many first‐trimester exposures to opioids occur before pregnancy confirmation. Studies are limited about the fetal risks to opioid exposure in early pregnancy. One large study demonstrated an increased risk of certain heart defects and spina bifida with first‐trimester exposure to opioids. It is important to counsel women whose fetuses were exposed to opioids in early pregnancy about the potential risks, encourage them to cease using opioids or seek alternative treatments when appropriate, and use the lowest effective dose when opioid treatment is to be continued. It is also valuable to screen for anatomic abnormalities such as neural tube and cardiac defects with available maternal serum testing and ultrasound imaging in the early second trimester. Birth Defects Research (Part A) 94:620–625, 2012. © 2012 Wiley Periodicals, Inc.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Nouveau-Mexique</li></region></list><tree><country name="États-Unis"><region name="Nouveau-Mexique"><name sortKey="Brennan, Matthew C" sort="Brennan, Matthew C" uniqKey="Brennan M" first="Matthew C." last="Brennan">Matthew C. Brennan</name></region><name sortKey="Brennan, Matthew C" sort="Brennan, Matthew C" uniqKey="Brennan M" first="Matthew C." last="Brennan">Matthew C. Brennan</name><name sortKey="Brennan, Matthew C" sort="Brennan, Matthew C" uniqKey="Brennan M" first="Matthew C." last="Brennan">Matthew C. Brennan</name><name sortKey="Rayburn, William F" sort="Rayburn, William F" uniqKey="Rayburn W" first="William F." last="Rayburn">William F. Rayburn</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E49 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E49 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A9FC8F07129E3C3062B52166DECFB33015BBF83D
|texte= Counseling about risks of congenital anomalies from prescription opioids
}}
| This area was generated with Dilib version V0.6.33. |  |